title: The effects of glucose-insulin-potassium solution and BN 52021 in intestinal ischemia-reperfusion injury.
abstract: The objective of this study was to investigate effects of glucose-insulin-potassium (GIK) solution and BN 52021, a platelet-activating factor antagonist, on intestinal ischemia-reperfusion injury. Fifty male Sprague-Dawley rats (200-225 g) were divided into 5 groups each containing 10 rats; group SO, sham operation group; group I, mesenteric ischemia group (for 30 minutes); group R, ischemia plus reperfusion (for 60 minutes); group BR, ischemia-reperfusion plus BN 52021; group GR, ischemia-reperfusion plus GIK solution. Samples for malondialdehyde (MDA) and ileum (for mucosal injury score) were obtained. The mucosal injury scores of group R were significantly higher than those of group I (4 +/-0.20 and 3 +/-0.16, respectively, p<0.0001). The scores of groups BR and GR were significantly lower than those of group R (p<0.0001 and p<0.0001, respectively). When it was compared with the injuries in BR and GR groups, similar results were obtained in both groups (p=0.190). Mean MDA levels of group R were significantly higher than those of group I, BR and GR (131.33 +/-3.99 nmol/g, 93.74 +/-3.22 nmol/g, 104.81 +/-2.56 and 100.34 +/-5.30, respectively, p<0.0001). MDA levels of group BR and GR were significantly lower than those of group I (p<0.0001 and p=0.003, respectively). These observations suggest that treatment with GIK solution and BN 52021 before reperfusion and during reperfusion period may be useful in decreasing intestinal reperfusion injury.
authors.affiliation: Department of General Surgery, Dicle University, Faculty of Medicine, Turkey. maldemir21@hotmail.com
authors.forename: Mustafa
authors.initials: M
authors.lastname: Aldemir
authors.forename: Ahmet
authors.initials: A
authors.lastname: Gürel
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Büyükbayram
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Taçyildiz
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004224:Diterpenes / Q000494:pharmacology*; D046934:Ginkgolides; D005947:Glucose / Q000494:pharmacology*; D015601:Injury Severity Score; D007328:Insulin / Q000494:pharmacology*; D007410:Intestinal Diseases / Q000628:therapy*; D007783:Lactones / Q000494:pharmacology*; D008297:Male; D011188:Potassium / Q000494:pharmacology*; D011336:Probability; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D015427:Reperfusion Injury / Q000401:mortality / Q000628:therapy*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D004224:Diterpenes; D046934:Ginkgolides; D007328:Insulin; D007783:Lactones; C030396:glucose-insulin-potassium cardioplegic solution; C045856:ginkgolide B; D005947:Glucose; D011188:Potassium